116 related articles for article (PubMed ID: 1591054)
21. Coadministration of the aromatase inhibitor formestane and an isopropanolic extract of black cohosh in a rat model of chemically induced mammary carcinoma.
Nisslein T; Freudenstein J
Planta Med; 2007 Apr; 73(4):318-22. PubMed ID: 17354167
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics and metabolism of formestane in breast cancer patients.
Lønning PE; Geisler J; Johannessen DC; Gschwind HP; Waldmeier F; Schneider W; Galli B; Winkler T; Blum W; Kriemler HP; Miller WR; Faigle JW
J Steroid Biochem Mol Biol; 2001 Apr; 77(1):39-47. PubMed ID: 11358673
[TBL] [Abstract][Full Text] [Related]
23. Second generation aromatase inhibitor--4-hydroxyandrostenedione.
Dowsett M; Coombes RC
Breast Cancer Res Treat; 1994; 30(1):81-7. PubMed ID: 7949207
[TBL] [Abstract][Full Text] [Related]
24. Treatment of advanced breast cancer in postmenopausal women with 4-hydroxyandrostenedione.
Stein RC; Dowsett M; Hedley A; Davenport J; Gazet JC; Ford HT; Coombes RC
Cancer Chemother Pharmacol; 1990; 26(1):75-8. PubMed ID: 2322991
[TBL] [Abstract][Full Text] [Related]
25. Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer.
Dowsett M; Doody D; Miall S; Howes A; English J; Coombes RC
Breast Cancer Res Treat; 1999 Jul; 56(1):25-34. PubMed ID: 10517340
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer.
Pérez Carrión R; Alberola Candel V; Calabresi F; Michel RT; Santos R; Delozier T; Goss P; Mauriac L; Feuilhade F; Freue M
Ann Oncol; 1994; 5 Suppl 7():S19-24. PubMed ID: 7873457
[TBL] [Abstract][Full Text] [Related]
27. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study.
Celio L; Martinetti A; Ferrari L; Buzzoni R; Mariani L; Miceli R; Seregni E; Procopio G; Cassata A; Bombardieri E; Bajetta E
Anticancer Res; 1999; 19(3B):2261-8. PubMed ID: 10472341
[TBL] [Abstract][Full Text] [Related]
28. Pilot study of formestane in postmenopausal women with breast cancer.
Joseph JK; Lim AK
Med J Malaysia; 1998 Mar; 53(1):37-41. PubMed ID: 10968135
[TBL] [Abstract][Full Text] [Related]
29. Plasma and urinary oestrogens in breast cancer patients on treatment with 4-hydroxyandrostenedione.
Johannessen DC; Adlercreutz H; Fotsis T; Lønning PE
Br J Cancer; 1993 Aug; 68(2):393-8. PubMed ID: 8135918
[TBL] [Abstract][Full Text] [Related]
30. Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancer.
Cunningham D; Powles TJ; Dowsett M; Hutchison G; Brodie AM; Ford HT; Gazet JC; Coombes RC
Cancer Chemother Pharmacol; 1987; 20(3):253-5. PubMed ID: 3677299
[TBL] [Abstract][Full Text] [Related]
31. The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients.
Zilembo N; Bajetta E; Bichisao E; Martinetti A; La Torre I; Bidoli P; Longarini R; Portale T; Seregni E; Bombardieri E
Biomed Pharmacother; 2004 May; 58(4):255-9. PubMed ID: 15183852
[TBL] [Abstract][Full Text] [Related]
32. Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study.
Höffken K; Jonat W; Possinger K; Kölbel M; Kunz T; Wagner H; Becher R; Callies R; Friederich P; Willmanns W
J Clin Oncol; 1990 May; 8(5):875-80. PubMed ID: 2185341
[TBL] [Abstract][Full Text] [Related]
33. Severe immune thrombocytopenia during formestane treatment.
Español I; Muñíz-Díaz E; Alonso MC; Pujol-Moix N
Haematologica; 1998 Oct; 83(10):953-4. PubMed ID: 9830809
[TBL] [Abstract][Full Text] [Related]
34. Formestane as treatment of advanced breast cancer in elderly women.
Zilembo N; Buzzoni R; Celio L; Noberasco C; Ferrari L; Laffranchi A; Vicario G; Dolci S; Bajetta E
Tumori; 1994 Dec; 80(6):433-7. PubMed ID: 7900232
[TBL] [Abstract][Full Text] [Related]
35. Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer.
Johnston SR; Smith IE; Doody D; Jacobs S; Robertshaw H; Dowsett M
Cancer Res; 1994 Nov; 54(22):5875-81. PubMed ID: 7954417
[TBL] [Abstract][Full Text] [Related]
36. 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer.
Coombes RC; Goss P; Dowsett M; Gazet JC; Brodie A
Lancet; 1984 Dec; 2(8414):1237-9. PubMed ID: 6150277
[TBL] [Abstract][Full Text] [Related]
37. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK).
Thürlimann B; Castiglione M; Hsu-Schmitz SF; Cavalli F; Bonnefoi H; Fey MF; Morant R; Löhnert T; Goldhirsch A
Eur J Cancer; 1997 Jun; 33(7):1017-24. PubMed ID: 9376181
[TBL] [Abstract][Full Text] [Related]
38. 4-hydroxyandrostenedione--further clinical and extended endocrine observations.
Pickles T; Perry L; Murray P; Plowman P
Br J Cancer; 1990 Aug; 62(2):309-13. PubMed ID: 2386749
[TBL] [Abstract][Full Text] [Related]
39. Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy.
Harper-Wynne C; Coombes RC
Eur J Cancer; 1999 May; 35(5):744-6. PubMed ID: 10505035
[TBL] [Abstract][Full Text] [Related]
40. Formestane for advanced breast cancer in postmenopausal women.
Drug Ther Bull; 1993 Oct; 31(22):85-7. PubMed ID: 8269826
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
